Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Equity Average (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Equity Average for 13 consecutive years, with -$281.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average fell 62.64% year-over-year to -$281.1 million, compared with a TTM value of -$281.1 million through Dec 2025, down 62.64%, and an annual FY2025 reading of -$239.5 million, down 48.64% over the prior year.
  • Equity Average was -$281.1 million for Q4 2025 at Karyopharm Therapeutics, down from -$254.1 million in the prior quarter.
  • Across five years, Equity Average topped out at $5.5 million in Q1 2021 and bottomed at -$281.1 million in Q4 2025.
  • Average Equity Average over 5 years is -$126.0 million, with a median of -$111.4 million recorded in 2021.
  • The sharpest move saw Equity Average plummeted 1592.32% in 2022, then soared 62.01% in 2023.
  • Year by year, Equity Average stood at -$102.8 million in 2021, then rose by 23.69% to -$78.5 million in 2022, then tumbled by 50.76% to -$118.3 million in 2023, then plummeted by 46.1% to -$172.8 million in 2024, then tumbled by 62.64% to -$281.1 million in 2025.
  • Business Quant data shows Equity Average for KPTI at -$281.1 million in Q4 2025, -$254.1 million in Q3 2025, and -$222.4 million in Q2 2025.